The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

The ad from the telehealth company Hims & Hers promoted the company’s compounded weight loss drugs. The ad portrayed the ...

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.

For example, Brittany found that drugs being developed by Generate were modified versions of existing antibodies, and that ...

The ad was graded as an “A” by the Kellogg students and place 9 th on AdMeter. It also made iSpot Tv’s list of the most ...

Although it has not been approved for NHS use solely as a weight-loss treatment, the rising demand for such drugs could lead to supply shortages. This risks depriving diabetes patients of ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were ... an average weight loss of 20.7% ...